We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Eliminating H. pylori Reduces Risk of Gastric Cancer Recurrence

By HospiMedica International staff writers
Posted on 18 Aug 2008
A new study shows that eradicating the bacteria Helicobacter pylori after surgery of patients with early gastric cancer greatly reduces the risk of gastric cancer reemerging.

Researchers at Yamagata Prefectural Central Hospital (Japan) conducted a multi-center, open-label, randomized controlled trial that involved 544 patients with early gastric cancer. More...
Patients underwent endoscopic resection and subsequent endoscopy at 6, 12, 24, and 36 months after surgery. Half the patients were randomized to receive treatment to eradicate H. pylori infection, with a combination of lansoprazole, amoxicillin, and clarithromycin twice daily for a week; the other half of the patients acted as a control group, but did not receive placebo. The primary endpoint was diagnosis of new carcinoma at another site in the stomach. For ethical reasons, after the final analysis, patients in the control group were also given eradication therapy, as were patients in the eradication group who still had an active H. pylori infection. The study results showed that at three-year follow-up, metachronous (not occurring at the same time) gastric carcinoma had developed in 9 patients in the eradication group and 24 in the control group. In the full intention-to-treat population, including all patients irrespective of length of follow-up (272 patients in each group), the odds ratio for metachronous gastric carcinoma was 0.353. In the eradication group, 19 (7%) patients had diarrhea and 32 (12%) had soft stools. The study was published in the August 2, 2008, issue of the Lancet.

"Prophylactic eradication of H. pylori after endoscopic resection of early gastric cancer should be used to prevent the development of metachronous gastric carcinoma,” concluded lead author Kazutoshi Fukase, M.D., and colleagues of the department of gastroenterology.

H. pylori is a gram-negative, microaerophilic bacterium that inhabits various areas of the stomach and duodenum. The bacterium causes a chronic low-level inflammation of the stomach lining and it is strongly linked to the development of peptic ulcers and stomach cancer. More people are infected with H. pylori than any other species of bacteria, and 50% or more of the population harbor it; it is more prevalent in developing countries. Two related mechanisms by which H. pylori could promote cancer have been proposed; one mechanism involves the enhanced production of free radicals near H. pylori and an increased rate of host cell mutation. The other mechanism involves enhancement of the transformed host cell phenotype by means of alterations in cell proteins such as adhesion proteins.

Related Links:
Yamagata Prefectural Central Hospital



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.